Sachs Associates’ Post

Phialogics is a preclinical biotech company specialized in engineering next-generation biologics to rebalance the immune response in acute and chronic inflammation. Phialogics concept is based on the targeted modification of immunoglobulin receptor domains (IgVs) to modulate immune response in inflammatory diseases. IgV mediated receptor-ligand interaction represents a significant source of novel biologics. Phialogics lead molecules replicate endogenous protein-protein interactions to efficiently modulate the function of their target receptor. So far, only this unique platform technology can achieve such a high level of precision. Meet Phialogics AG @ #Sachs_ELSF More Info @ https://lnkd.in/dQWhKYkV #ELSF2024 #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #RisingStars #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #SachsSpringLifeSciencesWeek #SSLSW

🔬 We're thrilled to offer a glimpse into the Tumor Microenvironment Track at our upcoming Immuno-Oncology Xchange event in Boston! 🎉 📌Secure your spot and register for free: https://bit.ly/4clU9OU Don't miss this opportunity to explore more into tumor microenvironment in immuno-oncology! Connect with industry experts and gain valuable insights! ⭐ Here's the highlights: 📑 Learning from patient-derived autoantibodies to understand human tumor biology and identify new targets. 🗣️ Xingfeng Bao, VP Head of Biology, GV20 Therapeutics 📑 How to overcome suppressive Tumor Microenvironment, Mechanism, Hurdles, and Innovative Therapeutic Modalities. 🗣️ Dharini Shah, Senior Director (Cell Therapy, Oncology), Sanofi 💊 Only available for Senior Scientists and above, from Bio and Pharma companies with a drug pipeline. 💊 🤝 Our Partners ‣ Biorasi ‣ Enable Medicine ‣ Oncocyte Corporation ‣ Flagship Biosciences, Inc. ‣ WuXi Advanced Therapies ‣ CDI Labs ‣ Nona Biosciences * Agenda subject to change. #ImmunoOncology #CancerResearch #Biotech #Pharma #TumorMicroenvironment #BostonEvents #PharmaEvent #NetworkingEvent #IOtherapy #CancerTherapies #OncologyResearch #BostonNetworking #OncologyInnovation #CancerTreatment #PrecisionMedicine #DrugDevelopment #Biopharma #Bioinformatics #MedicalResearch #Healthcare #BostonLifeScience #InnovationInHealth #ClinicalTrials #BiomarkerDiscovery #ScienceNetworking #ResearchCollaboration #BiomedicalScience #PrecisionOncology #HealthInnovation #hubXchange #Xchanges #Roundtable #FreePass #RegisterNow #ComplimenatryPass

Allow us to share with you the joy of our recent investment in Lime Therapeutics 🔬 – US-based biotech startup developing a game-changing drug discovery platform. Using an ultrasensitive lipid detection technology, the platform is able to target conditions such as cancer, metabolic disorders, and neurodegenerative diseases. Founded by a team with expertise in immunology, nanosensor technologies, and drug discovery, Lime Therapeutics has established relevant partnerships with pharmaceutical companies. 🤝 Huge congrats to the core team | Shardule Shah, PhD, MBA | Prakrit Jena | Daniel Heller | Mariluz Soula, PhD | on their progress up to date and looking forward to watching their future path 🚀 For more info see the link to a full article in comments. #investment #startup #biotech #lipidmetabolism #lipidbiology #lipiddysfunction #cancersucks #stopcancer #drugdiscovery

Unveiling Growth Opportunities in the Global #OrphanDrug Industry ⚕️ Amidst the landscape of #rarediseases, the quest for innovative treatments intensifies, fueled by a convergence of advancements in #precisionmedicine, #informatics, and #oncology. Frost & Sullivan's latest analysis uncovers how emerging technologies like precision oncology and gene-editing techniques are reshaping the orphan drug (OD) industry. 🔗Dive into our comprehensive perspectives to seize the #growthopportunities in this dynamic sector 👉https://hubs.la/Q02sxhx-0 Robin Joffe | Nitin Naik | Nimisha Iyer | Sowmya Srinath | Unmesh Lal | Sudhakar Mishra | Aarti Natu Chitale | Surbhi Gupta | Sherin George | Shylesh Narayanan

According to the World Health Organization, AI-powered drug discovery platforms have slashed the time and cost of bringing new cancer drugs to market by up to 50%! This remarkable advancement is paving the way for the development of more targeted and effective therapies. By harnessing the power of artificial intelligence, researchers can sift through vast amounts of data and identify promising drug candidates with unprecedented speed and accuracy. This accelerated drug discovery process allows for quicker translation of scientific discoveries into life-saving treatments for cancer patients. #AIinOncology #PrecisionMedicine #CancerResearch #DrugDiscovery #ArtificialIntelligence #MedicalInnovation #HealthTech #PersonalizedMedicine #InnovationInHealthcare #CancerTreatment #HealthcareAI #ClinicalTrials #DigitalHealth #Biotechnology #OncologyResearch

🚀 Exciting News for Biotech Enthusiasts! 🚀 Hey LinkedIn family! 👋 Thrilled to share insights on a recent Nasdaq article by the insightful Ari Zoldan, highlighting six clinical-stage biotech stocks with groundbreaking treatments. 💡 In the ever-evolving biotech landscape, it's crucial to spot potential winners, and Ari has done an exceptional job curating a list of small- and micro-cap gems with promising science and focus areas. 🧬✨ Here's a sneak peek: 1️⃣ Coya Therapeutics, Inc. (COYA): Tackling neurodegenerative, autoimmune, and metabolic diseases with Tregs. Exciting developments in #Alzheimer's and #ALS treatments! 2️⃣ Arvinas (ARVN): Pioneering targeted protein degradation with PROTAC. Keep an eye on their advancements in breast cancer, prostate cancer, and neurodegenerative diseases. 3️⃣ Cormedix Inc. (CRMD): Combatting catheter-related bloodstream infections with innovative solutions. Impressive 71% reduction in CRBSI risk in Phase 3 trials! 4️⃣ Ocuphire Pharma (OCUP): Focusing on retinal and refractive eye disorders. APX3330, their lead candidate for diabetic retinopathy, is making waves! 5️⃣ Rocket Pharmaceuticals (RCKT): Groundbreaking genetic therapies addressing rare illnesses. LV RP-L201 for leukocyte adhesion deficiency in FDA review - results expected March 31, 2024! 6️⃣ Ventyx Biosciences (VTYX): Innovating oral therapies for autoimmune and inflammatory diseases. VTX958, their lead candidate for psoriasis, is moving beyond Phase 2 trials! 🚨 Investing Considerations: Ari wisely cautions about the volatility in the biotech sector. As always, diligence is key! 🔍 🔗 Read the full article by Ari Zoldan: https://lnkd.in/gkgCiGTT 💬 Engage with this post, share your thoughts on these biotech disruptors, and let's foster a community of knowledge exchange! #Biotech #Innovation #Investing #AriZoldan #KnowledgeSharing

Unveiling Growth Opportunities in the Global #OrphanDrug Industry ⚕️ Amidst the landscape of #rarediseases, the quest for innovative treatments intensifies, fueled by a convergence of advancements in #precisionmedicine, #informatics, and #oncology. Frost & Sullivan's latest analysis uncovers how emerging technologies like precision oncology and gene-editing techniques are reshaping the orphan drug (OD) industry. 🔗Dive into our comprehensive perspectives to seize the #growthopportunities in this dynamic sector 👉https://hubs.la/Q02sxhyW0 Robin Joffe | Nitin Naik | Nimisha Iyer | Arun Stanly | Abdulaziz Jalab | Hani Al Sayed | Reenita Das | Sherin George

BIG pharma invests $500m in CGT this week, 𝗛𝗲𝗿𝗲'𝘀 𝟯 𝗲𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝗻𝗲𝘄 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽𝘀 👇 1. 𝐕𝐞𝐫𝐭𝐞𝐱 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥𝐬 and 𝐓𝐫𝐞𝐞𝐅𝐫𝐨𝐠 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 have announced a collaboration to enhance the production of cell therapies for 𝐭𝐲𝐩𝐞 1 𝐝𝐢𝐚𝐛𝐞𝐭𝐞𝐬 . Vertex has acquired an exclusive license to TreeFrog's C-StemTM technology, aiming to optimise the manufacturing process for T1D therapies. 2. 𝐁𝐌𝐒 and 𝐂𝐞𝐥𝐥𝐚𝐫𝐞𝐬 have entered a $380million agreement for the manufacturing of CAR T cell therapies, aiming to expand access to these therapies for patients. BMS will utilise 𝐂𝐞𝐥𝐥𝐚𝐫𝐞𝐬' 𝐂𝐞𝐥𝐥 𝐒𝐡𝐮𝐭𝐭𝐥𝐞, an advanced automated manufacturing platform, for clinical and commercial-scale production of specific CAR T cell therapies 𝐢𝐧 𝐭𝐡𝐞 𝐔.𝐒., 𝐄𝐔, 𝐚𝐧𝐝 𝐉𝐚𝐩𝐚𝐧. 3. 𝐋𝐞𝐱𝐞𝐨 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 has secured IP rights from Cornell University, following years of partnership aimed at advancing its gene therapy LX2006 for Friedreich ataxia cardiomyopathy. This therapy targets mitochondrial function and is a significant step in advancing their clinical progress. #celltherapy #genetherapy #biotech #CGTweekly

Exciting prospects for 2024 in pharma and biotech: - Increased investment in vital clinical research. - Advancements in obesity treatments and neurology breakthroughs. - Progress in Alzheimer's and gene editing technologies. - Thriving oncology research landscape. - Ongoing challenges in trial recruitment, emphasizing the need for patient-centric approaches and diversity initiatives. - Integration of AI promising personalized healthcare solutions. - Collaboration between tech and healthcare sectors driving innovation and improving patient outcomes. #pharmaceutical #biotech #innovation #healthcareinnovation #ai #researchanddevelopment https://lnkd.in/eeUPZAJt

Eleva uses its proprietary moss cell culture (Bryotechnology) to produce highly complex and difficult to express biopharmaceuticals with optimized human-like glycosylation. The first moss-based protein has been successfully tested in a clinical trial. RPV-001: recombinant alpha-galactosidase enzyme for the treatment of Fabry disease as an enzyme replacement therapy, clinical safety confirmed in phase I study. CPV-104: extensive pre-clinical testing completed (dry AMD, PNH, C3G, ANCA, lupus nephritis), toxicity studies ongoing, potential treatment for multiple complement indications. Bryotechnology provides a highly robust production platform that can be run in state-of-the-art bioreactors over a wide range of temperature and pH conditions. Stability, consistency, and homogeneity of N-glycosylation are remarkable and less affected by process conditions and scale. The GMP-compliant system is easily transferable and is known for its batch-to-batch stability and safety. By using simple culture media and avoiding virus filtration systems, even challenging proteins can be produced in a cost-effective manner. The platform is available for out-licensing. The Eleva team is eager to tackle the most challenging molecules. We welcome your enquiries regarding strategic partnerships, collaborations, co-development, and licensing of RPV-001, CPV-104 and the Bryotechnology platform. Meet eleva @ #Sachs_ELSF More Info @ https://lnkd.in/dQWhKYkV #ELSF2024 #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #RisingStars #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #SachsSpringLifeSciencesWeek #SSLSW